Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix to Apply for Transfer of Shares to Nasdaq Capital Market

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix said after the close of the market Thursday that its board of directors has authorized management of the firm to voluntarily apply to have its stock transferred to the Nasdaq Capital Market from the Nasdaq Global Market.

The firm has decided to take this action rather than submit a plan to the exchange to regain compliance with Nasdaq Global Market listing requirements.

As reported last week on GenomeWeb Daily News, CombiMatrix received a notice from Nasdaq that it does not meet listing requirements and could be delisted from the Nasdaq Global Market. Specifically, Nasdaq said that CombiMatrix's stock equity is below the minimum listing requirement of $10 million.

The Nasdaq Capital Market has a minimum listing requirement of $2.5 million in stock equity. As of the end of its third quarter, Sept. 30, the company had $9.3 million in shareholders' equity.

CombiMatrix said that its management intends to submit the listing transfer application within the next week.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.